Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
By G. Bergers, R. Brekken, G. Mcmahon, Thiennu H. Vu, T. Itoh, K. Tamaki, K. Tanzawa, P. Thorpe, S. Itohara, Zena Werb and 1 more. Nature Cell Biology, 2000
2,860 citations recorded by the source corpus.
Subfields: Cancer Research, Cell Biology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/779c64a2168ae6fbf20b21c2ccc966e423cfeba8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Cell Biology
In Molecular Biology
Citations in the corpus
- Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. (2007, background): “In this cancer model, every mouse developed pancreatic islet tumors by 12 to 14 weeks of age (17).”
- Osteogenesis and angiogenesis: the potential for engineering bone. (2008, background): “VEGF binds to the extracellular matrix and is made available by MMP-9 (Bergers et al., 2000).”
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer (2004, background): “Furthermore, as discussed later in this article, proteolysis of VEGF mediated by matrix metalloproteinase-9 (MMP9) might be responsible for the angiogenic switch in some tumour”
- Extracellular matrix remodelling: the role of matrix metalloproteinases (2003, background): “MMP deletion 2 RIP-Tag Reduced pancreatic carcinogenesis [102] 7 ApcMin Reduced Intestinal adenoma formation [140]”
- The role of myeloid cells in the promotion of tumour angiogenesis (2008, background): “, and so could promote angiogenesis by the extracellular matrix-degrading properties of this enzyme that were mentioned previousl”
- Progress in matrix metalloproteinase research. (2008, background): “Various types of proteinases have been implicated in ECM degradation, but a major enzyme group involved is that of the matrix metalloproteinases (MMPs), also called the matrixins.”
- Roles of the immune system in cancer: from tumor initiation to metastatic progression (2018, background): “Moreover, TANs contribute to the tumor angiogenesis by the secretion of MMP9 and VEGF in genetic mouse models of pancreatic and colon cancer (Bergers et al. 2000; Shojaei et al. 2007, 2008).”
- Physiology and pathophysiology of matrix metalloproteases (2010, background): “This process is complemented by the direct proteolytic degradation of vascular basement membrane proteins, indicating that MMP-9 (even more than MMP-2) may play a crucial role in the formation of new blood vessels (Bergers et al. 2000).”
- The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis. (2017, positive): “Furthermore, the actions of MMP-9 both break down the fibrous collagen matrix to make space for new blood vessels and release matrix-bound VEGF (53).”
- Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. (2001, background): “Similarly, MMP-9 is now regarded as a specific component of the angiogenic switch, because it renders VEGF more available to its receptors and its inhibitors impair angiogenesis and tumor growth (33).”
- Gelatinase-mediated migration and invasion of cancer cells. (2005, background): “MMP-9 has been observed to decrease cancer-cell apoptosis (Bergers et al., 2000), whereas developmental apoptosis is augmented (Vu et al., 1998).”
- Rapid vascular regrowth in tumors after reversal of VEGF inhibition. (2006, methodology): “In RIP-Tag2 tumors, VEGF is stored not only in tumor cells (39, 40) but also on empty sleeves of basement membrane.”